Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Authors:
- 1 June 2021
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (6) , e433-e445
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
This publication has 27 references indexed in Scilit:
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin FailureJournal of Clinical Oncology, 2016
- Hodgkin lymphoma: 2016 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2016
- 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphomaProceedings of the National Academy of Sciences, 2015
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndromeLeukemia & Lymphoma, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerJournal of Clinical Oncology, 2011
- Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid TumorsClinical Cancer Research, 2011